The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19

Completed

• Conditions: Coronavirus Disease 2019; Character of the Severe Patients
• Interventions: Other: no intervention

• Registration Number: NCT04403009
• Lead Sponsor: The First Affiliated Hospital of Guangzhou Medical University

Brief Summary

To investigate the difference of the difference between the nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the fatal Patients .The cross sectional study was undertaken to compare the clinical information (laboratory and radiologic characteristics)of nonfatal participants and fatal cases. The investigators wish figure out the clinical character of the fatal participants. The result may help the physician to find the fatal patients with COVID-19 more easily. The fatal patients with COVID-19 could be treated early.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-02-01
• Study First Submitted: 2020-04-21
• Study First Submitted QC: 2020-05-24
• Study First Posted: 2020-05-27
• Primary Completion: 2020-06-06
• Study Completion: 2020-06-20
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-04
• Last Update Posted: 2023-03-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• The patients with Coronavirus Disease 2019
• Positive result on real-time reverse-transcriptase-polymerase-chain-reaction
• Positive result on chest computed tomography

Exclusion Criteria

• No

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
the nonsevere Coronavirus Disease 2019 Patients	no intervention	-
the severe Coronavirus Disease 2019 Patients	no intervention	-

Primary Outcome Measures

Name	Time	Method
LDH	2 month	lactate dehydrogenase ( U/L)
CK	2 month	creatine kinase (U/L)
NK cell	2 month	natural killer cell(counts/L)
IL-6	2 month	interleukin-6(mg/L)
PT	2 month	prothrombin time(second)
AST	2 month	aspartate aminotransferase(U/L)
CRP	2 month	the level of C-reactive protein (mg/uL)
PCT	2 month	procalcitonin（ng/ml）
PLT	2 month	the counting of Platelets（(counts/L)）
Lymphocyte cell	2 month	the counting of Lymphocyte(counts/L)
ALT	2 month	alanine aminotransferase(U/L)
d-dimer	2 month	d-dimer（mg/L）

Secondary Outcome Measures

Name	Time	Method
the clinical difference of radiologic characteristics between the fatal patients with COVID -19 and the non fatal cases	2 months	CT scan feature

Trial Locations

Locations (2)

The First Affiliated Hospital of Guangzhou Medical University; 🇨🇳 Guanzhou, Guangdong, China

Hankou Hospital; 🇨🇳 Wuhan, Hubei, China